Zydus Lifesciences Limited has announced its unaudited consolidated financial results for the quarter and nine months ended 31 December 2025, posting robust growth across revenue, profitability, and research investments.
Revenue from operations surged 30% year-on-year to Rs. 68,645 million. Research & Development (R&D) spend reached Rs. 6,074 million, or 8.8% of revenue. EBITDA jumped 31% to Rs. 18,164 million, with margins improving 20 basis points to 26.5%. Adjusted net profit rose 9% to Rs. 11,109 million. Organic capital expenditure totaled Rs. 4,637 million.
Similarly, in 9M FY26, revenue climbed 17% to Rs. 1,95,614 million. R&D investment stood at Rs. 15,750 million, representing 8.1% of revenue. EBITDA increased 20% to Rs. 59,207 million, with margins rising 80 basis points to 30.3%. Adjusted net profit grew 15% to Rs. 38,640 million. Organic capex for the nine months was Rs. 13,568 million. And net debt-to-equity ratio remained low at 0.11x, while net debt-to-EBITDA stood at 0.36x.
Adjusted profits account for a one-time Rs. 849 million expense in Q3 FY26 due to increases in gratuity and leave encashment liabilities under the new labor code, and a Rs. 342 million acquisition-related cost in Q2 FY26, including tax impact.
Commenting on the results, Sharvil Patel, Managing Director of Zydus Lifesciences Limited, said: "Our robust performance in 3QFY26 across key businesses reinforces the strength and scalability of our base business. Our disciplined M&A and business development strategy is translating into tangible results, laying a strong foundation for sustained value creation.
"Anchored in patient centricity, supported by unwavering compliance and an agile supply chain, we continue to deliver quality products globally. We remain focused on consistent execution and driving long-term shareholder value."
